463 related articles for article (PubMed ID: 35152998)
1. Generation of CAR-T cells using lentiviral vectors.
Poorebrahim M; Quiros-Fernandez I; Fakhr E; Cid-Arregui A
Methods Cell Biol; 2022; 167():39-69. PubMed ID: 35152998
[TBL] [Abstract][Full Text] [Related]
2. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
[TBL] [Abstract][Full Text] [Related]
3. Generation of CAR+ T Lymphocytes Using the Sleeping Beauty Transposon System.
Chicaybam L; Abdo L; Bonamino MH
Methods Mol Biol; 2020; 2086():131-137. PubMed ID: 31707672
[TBL] [Abstract][Full Text] [Related]
4. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models.
Sawaisorn P; Atjanasuppat K; Uaesoontrachoon K; Rattananon P; Treesuppharat W; Hongeng S; Anurathapan U
PLoS One; 2023; 18(2):e0281735. PubMed ID: 36780428
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Nonviral
Lin Z; Liu X; Liu T; Gao H; Wang S; Zhu X; Rong L; Cheng J; Cai Z; Xu F; Tan X; Lv L; Li Z; Sun Y; Qian Q
Front Immunol; 2021; 12():802705. PubMed ID: 35082789
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
[TBL] [Abstract][Full Text] [Related]
8. Optimized Production of Lentiviral Vectors for CAR-T Cell.
Moço PD; de Abreu Neto MS; Fantacini DMC; Picanço-Castro V
Methods Mol Biol; 2020; 2086():69-76. PubMed ID: 31707668
[TBL] [Abstract][Full Text] [Related]
9. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
[TBL] [Abstract][Full Text] [Related]
10. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
Front Immunol; 2019; 10():3123. PubMed ID: 32117200
[TBL] [Abstract][Full Text] [Related]
11. Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells.
Xiong W; Chen Y; Kang X; Chen Z; Zheng P; Hsu YH; Jang JH; Qin L; Liu H; Dotti G; Liu D
Mol Ther; 2018 Apr; 26(4):963-975. PubMed ID: 29503199
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
13. Generation of CAR-T Cells for Cancer Immunotherapy.
Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis and optimization of protocols for producing recombinant lentivirus carrying the anti-Her2 chimeric antigen receptor gene.
Yuan W; Chen J; Cao Y; Yang L; Shen L; Bian Q; Bin S; Li P; Cao J; Fang H; Gu H; Li H
J Gene Med; 2018 Jul; 20(7-8):e3027. PubMed ID: 29851200
[TBL] [Abstract][Full Text] [Related]
15. Generation of Chimeric Antigen Receptor T Cells Using Gammaretroviral Vectors.
Mo F; Mamonkin M
Methods Mol Biol; 2020; 2086():119-130. PubMed ID: 31707671
[TBL] [Abstract][Full Text] [Related]
16. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
[TBL] [Abstract][Full Text] [Related]
17. CAR T-cell therapy: Full speed ahead.
Sermer D; Brentjens R
Hematol Oncol; 2019 Jun; 37 Suppl 1():95-100. PubMed ID: 31187533
[TBL] [Abstract][Full Text] [Related]
18.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
19. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
20. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P
Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
